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Summary.-Misonidazole (MISO) potentiates the action of cyclophosphamide (CY)
and melphalan in the WHFIB culture-adapted fibrosarcoma, whether assayed by
cell survival ortumour-growth delay. In the case of CY, MISO also inhibited recovery
from potentially lethal drug damage. The optimum effect was seen when MISO
was given 1 h before CY, though it was also effective when given 6 h before or 1 h
after the drug. Other radiosensitizers also potentiated the action of CY. There was
only a small effect of MISO on the LD50 of CY and no effect on CY toxicity as assayed
by changes in blood counts or damage to bladder epithelium. However, mice bearing
multiple lung tumours were less able to cope with the combined treatment than those
bearing s.c. tumours.
THE HYPOXIC-CELL radiosensitizer mis-
onidazole (MISO) a 2-nitroimidazole, is
now being widely used in clinical trials
(Urtasun et al., 1977; Dische et al., 1980).
Two factors contributing to its sensitiz-
ing ability are its electron affinity and its
lipophilicity (Adams et al., 1976; Ander-
son & Patel. 1979). Recognition of these
factors has led to the investigation of
some related compounds. For radiosensi-
tization the drug must be present at the
time ofirradiation (McNally et al., 1978a).
The timing of drug injection relative to
irradiation is more critical in the mouse
than in man, because the drug's half-life
in the mouse is short (tf = 1-1- h) whereas
in man the average half-life is 12 h
(Flockhart et al., 1978a). As well as its
radiosensitizing ability, MISO has a direct
cytotoxic action, preferentially forhypoxic
cells, both in vitro and in vivo (Suther-
land, 1974; Hall & Roizin-Towle, 1975;
Brown, 1977). This effect is small com-
pared with its radiosensitizing effect, in
both mouse and man (Denekamp, 1978;
Denekamp & McNally, 1978).
Recent work has shown that the drug
also potentiates the cytotoxic effects of
chemotherapeutic agents, i.e. has a
"chemosensitizing" effect. Hypoxic V79
cells at physiological temperatures were
moreresistant to bleomycin thanwell-oxy-
genated cells, but in combination with
MISO they became more sensitive (Roizin-
Towle & Hall, 1978). MISO potentiated
the action of both melphalan and cis-
platinum in vitro (Stratford et al., 1980).
It potentiated the cytotoxic effects of
melphalan and cyclophosphamide (CY)
(both alkylating agents) on the Lewis
lung carcinoma (Rose et al., 1980). It
also potentiated the cytotoxic effects of
melphalan on marrow and gut crypt cells,
but to a lesser extent, suggesting an eni-
hanced therapeutic ratio.
The work described in this paper investi-
gates further the chemosensitizing effect
of MISO, using the two assay methods of
cell survival and regrowth delay. We have
worked principally with CY, but have also
used melphalan. We have also used other
2-nitroimidazoles and compared their
effectiveness with MISO, and have studied
the influence of timing and drug dose on
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chemosensitization. We report on the
toxicity which we observed using several
different endpoints.
MATERIALS AND METHODS
Tumours.-The tumour used, denoted
WHFIB, was a poorly differentiated sarcoma
derived from a fibrosarcoma which arose
spontaneously in inbred WHT mice. It was
adapted for growth in culture (George et al.,
1977) so that in vivo treatments can be
assayed either by cell survival in vitro or by
tumour-growth delay.
Methods of obtaining tumours.-Tumours
were grown either on the chest or as small
lung tumours. S.c. tumours were obtained by
first injecting 1-3 x 107 cultured cells into a
mouse, and transplanting the resulting tu-
mour 7-9 days later into the required number
of mice, as described by George et al. (1977).
Tumours reached treatment size, 6-8mm
diameter, 12-18 days later. Small lung tu-
mours were obtained by injecting 105 viable
cells together with 105 heavily irradiated non-
viable cells in a volume of0 5 ml medium into
the tail vein of a mouse. Nine days after in-
jection, lung tumours were invisible to the
naked eye, but 14 days after injection, 30-60
tumours of diameter up to 2 mm were visible
on the pleural surface. Ifleft intact the mouse
would remain well for 15-18 days after in-
jection, then become ill and have to be
killed at 19-21 days.
Cell-survival and growth delay assays.-To
assay cell survival, single-cell suspensions
from s.c tumours or whole lungs were ob-
tained as previously described (George et al.,
1977). The concentration of intact cells was
then measured with a haemocytometer and
a phase-contrast microscope. The appropriate
number of cells was plated on to 50mm Petri
dishes containing 5x 104 heavily irradiated
"feeder" cells, and the number of viable
colonies was counted 9-10 days later. The
plating efficiency was generally 25-40% for
s.c. tumours and 20-35% for lung tumours.
For the growth-delay assay, tumours treat-
ed at 6-8mm mean diameter were measured 3
times weekly in 3 mutually perpendicular di-
mensions andthetimecalculated foreachtum-
our to regrow to a geometric mean diameter
either 2mm or 3-5mm larger than the treat-
ment size. At treatment size the WHFIB
tumour has a doubling time of about 3-5
days. The drugs were administered i.p. as a
solution in normal saline. CY and melphalan
were used within 10 min of dissolving them.
Melphalan was first dissolved in a few tenths
of a ml of 2% HCI in ethanol before being
diluted in normal saline to the desired con-
centration. For each experiment the chemo-
therapeutic drugs were diluted such that a 30g
mouse would receive either 0 3 or 0-6 ml. The
radiosensitizing agents MISO, Ro 03-8799,
Ro 12-5272 and Ro 05-9963 were dissolved
at a concentration such that a 30g mouse
would receive 1 ml.
RESULTS
Subcutaneous tumours
Fig 1 shows the survival of cells from
s.c. WHFIB tumours after various doses
of CY. Survival depended on the time
betweeni treatment and the excision of the
tumour. Fig IA shows that, in spite of the
scatter, at each dose tumours excised at
2 h (open symbols) had a lower cell sur-
vival than tumours left in situ for 22-24 h
(closed symbols). Taking mean values we
see that after a dose of 150 mg/kg CY,
for example, cell survival rose by a decade
(Fig. IB). A rise of this magnitude can-
not be due to repopulation, since the cell-
cycle time is 12 h. We believe the in-
creaserepresentsrepairofpotentiallylethal
damage (PLD) in this system, as reported
by Twentyman (1977) for the EMT6
tumour.
When tumours were excised at differ-
ent times after a fixed dose (75 mg/kg)
of CY the same phenomenon was seen
(Fig. 2A); cell survival fell to a minimum
at 2-4 h and then increased. Other ex-
periments (data not shown) have shown
that most of the rise in survival was
completed by 12 h. However, when 1 g/kg
MISO was given and then 75 mg/kg CY
I h later, this rise in survival was not seen
(Fig. 2A). MISO potentiated cell kill by
CY at 2-4hbut causedgreaterpotentiation
at 20 h, due to this apparent inhibition
of PLD recovery. At 20 h the cell survival
in tumours treated by combined MISO +
CY was 50-100 times less than that in
tumours treated by CY alone. MISO alone
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FIG. 1. Cell survival in WHFIB tumours treated with CY: 0, at 2 h; 0, at 24 h. A, all values;
B, meanl values.
1
101
c
0
L._
(I) -3
10d
- A
I
\
/
I \ /
I
- O o
0
0
0
C-
c
.
0 ^-
0 N /
, 0
10Th
id
0
A
0 I I I I I
0 8 16 24
Time of excision(h) mg kg Cy
FIG. 2.-Cell survival in WHFIB tumours after: A: 0, 75mg/kg CY only; 0, mg/g MISO 1 h-75
mg/kg CY; A, mg/g MISO only. B, 24 h after; 0, CY only, varying closes; A, I mg/g MISO
-l h-CY.
-2
10
c
0
.4-
0
10
C
3 -2
10 10)
I I a I
758
31
4ENHANCEMENT OF CYTOTOXIC DRUGS BY RADIOSENSITIZERS
L)
a 20
E
E
Q)
N
C c
Li 0
a)
E
C Miso Cy Miso
lmg/g lOOmg/Kg IIh
Cy
FIG. 3. Time for WHFIB tumours to in-
crease in mean diameter by 2 mm after: no
treatment; 1 mg/g MISO only; 100 mg/kg
CYonly; or 1 mg/gMISO 1 h 100mg/kg
CY.
caused slight cell killing at 4 h in this
experiment (Fig. 2A), but this was not a
general finding and little cell kill was seen
at later times.
When tumours were excised at 24 h
after varying doses of CY preceded by 1
g/kg MISO, increased cell kill with the
combined treatment was again seen (Fig.
2B). The lines through the data points of
Fig. 2B were fitted by regression analysis,
assuming exponential survival curves.
With this assumption, MISO was dose-
modifying with a dose-modifying factor
of 2-0 + 0 4 (950 confidence limits).
The regrowth-delay assav was also used
to assess the potentiating effect of MISO
on CY cytotoxicity. Tumours were treated
with 100 mg/kg CY with or without 1 g/kg
MISO given 1 h earlier. The results are
shown in Fig. 3. CY alone caused 2*9
days delay in regrowth, whilst MISO
Sensitizing
agent
Misonidazole
Ro 03-8799
Ro 12-5272
Ro 05-9963
* See text.
52
Mol
wt
201 -2
290 - 8
219 - 2
187-2
E71/mV
-389
-346
-368
-389
Partition
coefficient
0-43
8 -5
0-05
0-11
alone caused none. However, MISO and
CY together caused 12-6 days delay in
regrowth, i.e. the MISO had "chemosensi-
tized" the tumours to the action of CY to
a highly significant extent.
We investigated the effects of other
radiosensitizers which differed from MISO
in their radiosensitizing efficiency and
lipophilicity. These were, in order of de-
creasing radiosensitizing efficiency in vitro,
Ro 03-8799, Ro 12-5272, MISO and Ro
05-9963 (Smithen et at., 1980; Adams et
al., 1979) (Table). The interval between
giving the radiosensitizers and CY was in
each case taken as the time at which
optimal radiosensitization in mouse tum-
ours would be observed. For MISO this
was 1 h, for Ro 03-8799 40 min and for
Ro 05-9963 and Ro 12-5272 30 min
(McNally et al., 1978b; McNally, un-
published). The dose of CY was always
75 mg/kg for survival assays and 100
mg/kg for growth-delay assays. Fig. 4A
shows that 1 g/kg Ro 03-8799 potentiated
CY toxicity when tumours were excised
at 4 h, and there was a further fall in
survival if excision was delayed for 22 h,
so that survival was then 2 decades lower
in tumours receiving CY only. Ro 05-9963
at 1-5 g/kg increased the cell kill by CY by
over a decade at 4 h, but some rise in
survival was seen by 24 h (Fig. 4B).
Neither of these 2-nitroimidazoles caused
significant cell killing when used alone.
Fig. 5 shows the effects of the different
sensitizers combined with CY on growth
delay. The effect of the combination of
sensitizer plus CY can be expressed in term
of the "excess delay", defined as the
growth delay duetothecombinationminus
that due to CY alone. The excess delay
for CY ranged fromn 12-3 days with 1 g/kg
TABLE
Acute
LD5o(g/kg)
2-0
1-8
3 -8
Dose
(g/kg)
1-0
1-0
0-2
1-0
Excess
delay
(days)
12 -3
10-1
5-6
2 2
Relative
chemosens.
efficiency*
I
1-2
2 -5
0-2
v Ia
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FIG. 5. Time for WHFIB tumours to
increase in mean diameter by 2 mm after
treatments as shown. Dose of CY, 100 mg/
kg in each case.
MISO to 2-2 days with 1 g/kg Ro 05-9963.
These values cannot be compared directly,
because the tumour concentration of the
sensitizers will be different and they have
different toxicities. Ro 12-5272 was rela-
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FIG. 6.-Excess delay, i.e. the time to in-
crease in mean diameterby 2 mm aftercom-
bined treatment minus the time to increase
in mean diameter by 2 mm after CY alone,
in WHFIB tumours following: A, varying
doses of MISO 30 min before 100 mg/kg
CY; B, varying doses ofRo 05-9963 30 min
before 100 mg/kg CY.
tively insoluble, and this limited its dose
to 0-2 g/kg. An approximately linear
relationship between excess delay and
dose of radiosensitizer was obtained for
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MISO and, with less certainty, for Ro
05-9963 (Fig. 6).
In order to determiine the effect of the
interval between MISO and CY, MISO was
given to tumour-bearing mice either 6 h or
1 h before CY, or simultaneously, or 2 h
after CY. The results are shown in Fig. 7,
in which the excess delay is plotted against
the interval between the drugs. The maxi-
mum effect was seen when the MISO
was injected 1 h before CY, as might have
been expected if the effect is largest when
CY is given at maximum MISO concen-
tration in the tumour. There was still a
considerable effect when it was given 6 h
before, and a small, but significant effect
when it was given 2 h after the CY. In
this experiment the MISO dose was re-
duced to 08 g/kg.
Fig. 8 shows the effect of CY alone or in
combination with MISO on tumours up
to 2 mm diameter growing in mouse lungs.
The animals were treated 16-18 days after
injection of the cells, and the lungs were
excised at various times after injection of
CY. Fig. 8A shows that, after a dose of 75
mg/kg, CY survival was the same whether
lungs were excised at 4-6 or 20 h, in-
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FIG. 8. Cell survival in WHFIB lung tumours after: A: 0, 75 mg/kg CY; 0, 1 mg/g M ISO lh-75
mg/kg CY; A, 1 mg/gMISO only. B: Cell survival in WHFIB lung tumours excised 4-6 h after:
O, CY only; A, 1 mg/g MISO 1 h CY. DMF= 1-4.
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dicating no recovery from PLD. In com-
bination with 1 g/kg MISO given 1 h
before CY, there was an enhancement of
cell kill at 4 and 6 h, with probably no
further change at 20 h. The single point
at 20 h was because the combination ofthe
2 drugs was found to be quite toxic to
mice bearing 16-18-day-old lung colonies,
in contrast to those bearing s.c. tumours.
This meant that 2/4 mice receiving both
MISO and CY died within 20 h. (In one
of those that survived, the tumour-cell
yield was unexpectedly low.) Thus the
data in Fig. 8 are limited. Nevertheless, it
implies that there was probably no re-
covery from potentially lethal drug dam-
age in these small lung tumours. Because
of this, and the toxicity of the combined
treatment, full dose-effect curves were
determined for tumours excised 4-6 h
after treatment (Fig. 8B). They have been
corrected for the toxicity of MISO alone,
which reduced the surviving fraction to
0 53 at 4-6 h. Comparison with Fig. 2
shows that the cells were more sensitive in
the lung tumours than in s.c. tumours.
The lines have been fitted assuming ex-
ponential inactivation and give a dose-
modifying factor (with 9500 confidence
limits) of 1-40 + 0-38.
The effect of MISO on the cytotoxicity
of melphalan was also studied. Fig. 9A
shows the survival of cells from WHFIB
tumours as a function of excision time
after a dose of 5 mg/kg melphalan, either
alone or preceded by 1 g/kg of MISO.
After melphalan alone (closed circles)
there was a small rise in cell survival be-
tween 4 and 22 h. When 1 g/kg MISO was
injected 1 h before melphalan (open circles)
there was potentiation of the cell kill at
4 h, and a greater potentiation at 22 h.
Circles with downward arrows refer to
points at which no colonies were counted,
and have been calculated as for one colony.
Fig. 8B shows survival curves for cells
from tumours excised at 24 h after vary-
ing doses of melphalan, either alone or
preceded by 1 g/kg MISO. The lines have
been fitted by regression analysis, assum-
ing exponential inactivation. MISO was
dose-modifying with a DMF of 2-7 + 07
(950 confidence limits).
N'ormal tissue toxicity
In non-tumour-bearing mice, I g/kg of
MISO 1 h before CY caused no signifi-
cant lowering of theLD50/60 of 260 mg/kg
due to CY alone.
Cystitis is a well-known side effect
of CY treatment, and is cauLsed by damage
to the bladder epithelium from contact
with acrolein (Cox, 1979). WVe therefore
attempted to assess whether cystitis was
increased by MISO treatment. The systetn
ofStewart et al. (1978) was used to measure
the hourly urination frequency of male
WHT mice. Mice were treated with 75 or
125 mg/kg CY, either alone or preceded by
I g/kg MISO 1 h earlier, with appropriate
controls. Theurination frequency ofgroups
of 5 mice was measured continuously for
10 days, then weekly up to one month.
75 mg/kg CY caused a marked increase in
frequency, which lasted for 10 days.
MISO decreased this frequency. In mice
receiving 125 mg/kg CY, there was no
increase in frequency over controls (per-
haps because oftheir reduced fluid intake),
yet their frequency was still decreased by
MISO. Mice treated with MISO alone
had a lower frequency then untreated
controls. After 2 weeks the frequencies of
all groups were the same. These findings
suggest that while MISO did not sensitize
the bladder epithelium to CY damage, at
least in terms of an increasing urination
frequency, there may have been effects on
fluid uptake. These would complicate the
interpretation of this result at the higher
drug dose, and so we cannot state un-
equivocally that there was no effect of
MISO on CY toxicity to the bladder,
though it appears to be minimal.
Leucopenia (fall in white-cell count)
and thrombocytopenia (fall in platelet
count) are important haematological side-
effects of CY. Samples of mouse tail blood
were taken to assess whether MISO in-
creased the leucopenia associated with a
dose of CY. After a dose of CY the white-
cell count fell to a nadir at 4 days, and
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returned to normal levels by 2-4 weeks
(Fig. IOA, B, C). If CY injection was pre-
ceded by 1 g/kg ofMISO 1 h earlier, there
was no further effect on the white-cell
count; MISO alonehadnoeffect (Fig. OD).
Thus, at therapeutic levels, there was no
enhancement by MISO ofthe effect of CY
on white-cell count.
DISCUSSION
Fig. 1 shows that in the s.c. WHFIB
tumour there was a rise in cell survival
between 2 and 24 h after a dose of CY.
This rise was too large to be accounted
for by repopulation. We believe that it is
due to repair of PLD, as reported earlier
by Twentyman (1977) using the EMT6
tumour. It follows from this that measure-
ments of tumour cell survival 1 day after
treatment are more likely to be correlated
with in situ tumour response than those
measured within a few hours, and so are
probably more relevant to the clinical
situation.
The 4 radiosensitizing drugs tested are
all of similar electron affinity (Table).
Radiobiological data on V79 cells in vitro
have shown MISO and Ro 05-9963 to be
of equal radiosensitizing efficiency, but
Ro 03-8799 and Ro 12-5272 are more
effective in vitro (Flockhart et al., 1978b;
Adams et al., 1979; Smithen et at., 1980;
Watts et al., 1980).
Ro 03-8799 sensitized tumours to Cy
at 4 and 22 h after treatment (Fig. 4A),
probably to the same extent as MISO (Fig.
2A). In these particular experiments the
CY controls did not clearly show the rise in
survival with time seen in other experi-
ments, but the survival in tumours re-
ceiving combined treatment nevertheless
fellbetween 4and 22h, sothat chemosensi-
tization was much greater at 22 h than at
4 h. For Ro 05-9963, Fig. 4B shows that
cell survival rose between 4 and 22 h after
combined treatment. This, combined
with the fact that the molar dose was
greater for Ro 05-9963 than for Ro
03-8799, suggests that Ro 05-9963 is a
less effective chemosensitizer (see below).
The tumour-growth delays were in
accordance with the in vitro data (Fig. 5).
The dose of Ro 12-5272 was only 02 g/kg,
because of its poor solubility. Ro 03-8799
has a mol.wt of290-8, comparedwith 201-2
for MISO (Table) so a dose of 1 g/kg for
Ro 03-8799 represents in molar terms
only 69% of a dose of 1 g/kg of MISO.
With MISO and Ro 05-9963 the dose-
response curves were nearly linear (Fig. 6).
Ifwe assume that this is so for all 4 radio-
sensitizing drugs, we can correct for dose
and molarity to give a relative "chemo-
sensitizing efficiency" compared with
MISO, fora chemosensitizing drugY,thus:
relative "chemosensitizing efficiency of
drug Y is:
excess delay with Y
excess delay with MISO
dose of MISO mol. wt Y x dose of Y xmol. wtMSO
The results of such calculations are
shown in the Table. On this basis Ro
03-8799 was amarginally better chemosen-
sitizer than MISO. Ro 12-5272 was clearly
more effective than MISO. Its mol.-wt is
similar to that of MISO (Table) so a
direct comparison can be made between
the two drugs. Figs. 5 and 6 show that
whereas 0f2 mg/g MISO would have caus-
ed virtually no extra growth delay the
same dose of Ro 12-5272 caused 5 days
extra delay. Ro 05-9963 was the least
effective sensitizer.
When the interval between the injection
of MISO and of CY was varied the extra
growth delay was best when MISO was
injected 1 h before CY (Fig. 7). However,
significant chemosensitization was also
found when MISO was given 6 h before CY
or even 2 h after. The tumour half-life
of MISO is short (McNally et al., 1978b),
so after 6 h a very small amount of the
MISO would be left in the tumour. It
follows that the large effect seen when
MISO is given 6 h before CY must be
a consequence of the damage done to the
cell by the MISO, and not of the quantity
of MISO left in the cell at 6 h. Similarly,
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the CY-induced damage must still be
capable of interaction with MISO 2 h
later.
MISO also sensitized the action of mel-
phalan on s.c. AW'HFIB tumours (Fig. 9).
The cell kill was potentiated at both 4 h
and 22 h after treatment. There was a
rise in survival between 4 and 22 h in
tumours treated with melphalan alone,
again suggesting PLD repair (Fig. 9B).
Because of the excessive cell kill it is not
clear whether or not PLD repair was in-
hibited by MISO. Stratford et al. (1980)
have found that MISO potentiates the
action of cis-platinum, which also acts as
an alkylating agent. Thus it is possible
that MISO and other 3-nitroimidazoles
sensitize tumours in vivo to the action of
the whole group of alkylating agents.
Small WHFIB lung tumours did not
show repair of PLD after CY (Fig. 8),
and there was less chemosensitization by
MISO than in the s.c. tumours. The treat-
ment was more toxic to mice bearing lung
tumours than to mice bearing s.c. tumours
of comparable cell numbers. Five out of 11
mice treated with doses of 25, 50 or 75 mg/
kg CY plus 1 mg/g MISO died within
20 h and 2/5 treated with MISO alone
died. No mice bearing s.c. tumours
showed any significant ill health as a
result of treatment with MISO 'or CY
or the two together. These experiments
were performed 16-18 days after i.v.
injection of tumour cells, at which time
the mice generally appeared well, but
contained 107-108 tumour cells in their
lungs. These would exert more adverse
physiological effects than 107-108 cells in
an s.c. tumour. It is perhaps not surprising
therefore, that the stress of the injections
of MISO and CY was more toxic to them.
The lack ofnormal-tissue toxicity due to
the combined treatment has been encour-
aging. The LD50/60d of CY in non-tumour-
bearing mice was not lowered signifi-
cantly by MISO. Frequency of urination
was not increased. The white-cell counts
after therapeutic levels of CY were not
significantly altered by 1 g/kg MISO
given 1 h earlier. It is possible that
tumour-bearing mice might be mnore
affected by the stress of the double treat-
mentthannon-tumour-bearing mice,owing
to the altered physiology in malignant
disease, so that the LD50 and blood counts,
for example, might show more difference
between the combined treatment and CY-
only in tumour-bearing animals than in
our experiments in non-tumour-bearing
animals. The toxicity in mice bearing
lung tumours suggests that the combina-
tion should be used with caution in ill
patients or those with lung metastases.
It must be borne in mind that the AISO
doses used throughout these experiments
were higher than those that can be used in
the clinic. For instance, in the 6-fraction
regime of Dishe et al. (1977) they used a
total of 12 g/m2, which is equivalent to
about 0'05 g/kg fraction. Thus the degree
of enhancement in human tumours may
be less than that seen inthese experiments.
However, the half-life of MISO in the
human is long compared with the mouse
(Flockhart et al., 1978a, b), which could be
advantageous. Also, standard chemo-
therapy regimes often require drugs to be
injected one or twice monthly, for instance
so that it might be possible to use higher
doses ofMISO with these longer intervals.
Alternatively, it may be possible to use
Ro 03-8799, or to design other drugs which
might be less toxic than MISO yet which
would be equally effective as chemosensi-
tizers.
The mechanisms whereby MISO enhan-
ced the action ofCY and melphalan are not
known. It is unlikely that there were such
significant alterations in the pharmaco-
kinetics of these two drugs that overall
exposure of the tumours increased suffici-
ently to cause such enhanced cell kill.
Since MISO potentiated the action of CY
more on tumour than on normal tissues,
hypoxic conditions may be necessary for
chemosensitization.
If chemosensitization were possible in
clinical cancer, the opportunity might
exist for improving the treatment of meta-
static disease. W\Te have shown that good
sensitization is possible, but only at sen-
76;5766 W. M. C. MARTIN, N. J. MCNALLY AND J. De RONDE
sitizer doses beyond the clinical range used
in radiotherapy. However, it may be
possible to find a combination of chemo-
sensitizer and cytotoxic agent which
could be effective on tumours at doses
within the clinical range.
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